Galectin Therapeutics, Inc. (GALT)
4.05
-0.09
(-2.17%)
USD |
NASDAQ |
Sep 09, 16:00
4.05
0.00 (0.00%)
After-Hours: 16:07
Galectin Therapeutics Enterprise Value : 401.23M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 401.23M |
| September 04, 2026 | 432.39M |
| September 03, 2026 | 415.15M |
| September 02, 2026 | 423.77M |
| September 01, 2026 | 403.22M |
| August 31, 2026 | 388.63M |
| August 28, 2026 | 393.27M |
| August 27, 2026 | 401.23M |
| August 26, 2026 | 401.89M |
| August 25, 2026 | 391.28M |
| August 24, 2026 | 383.99M |
| August 21, 2026 | 370.72M |
| August 20, 2026 | 363.43M |
| August 19, 2026 | 370.06M |
| August 18, 2026 | 360.11M |
| August 17, 2026 | 359.45M |
| August 14, 2026 | 354.81M |
| August 13, 2026 | 360.78M |
| August 12, 2026 | 334.91M |
| August 11, 2026 | 334.25M |
| August 10, 2026 | 333.59M |
| August 07, 2026 | 355.47M |
| August 06, 2026 | 340.22M |
| August 05, 2026 | 331.60M |
| August 04, 2026 | 324.64M |
| Date | Value |
|---|---|
| August 03, 2026 | 327.62M |
| July 31, 2026 | 323.64M |
| July 30, 2026 | 340.88M |
| July 29, 2026 | 358.12M |
| July 28, 2026 | 351.49M |
| July 27, 2026 | 350.83M |
| July 24, 2026 | 356.80M |
| July 23, 2026 | 355.47M |
| July 22, 2026 | 358.79M |
| July 21, 2026 | 381.66M |
| July 20, 2026 | 391.94M |
| July 17, 2026 | 403.55M |
| July 16, 2026 | 406.86M |
| July 15, 2026 | 442.34M |
| July 14, 2026 | 480.80M |
| July 13, 2026 | 431.73M |
| July 10, 2026 | 395.92M |
| July 09, 2026 | 416.48M |
| July 08, 2026 | 425.76M |
| July 07, 2026 | 432.39M |
| July 06, 2026 | 433.72M |
| July 02, 2026 | 425.76M |
| July 01, 2026 | 413.83M |
| June 30, 2026 | 434.38M |
| June 29, 2026 | 451.12M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
| Vericel Corp. | 1.932B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.113M |
| Total Expenses (Quarterly) | 9.113M |
| EPS Diluted (Quarterly) | -0.1393 |
| Earnings Yield | -10.61% |
| Normalized Earnings Yield | -9.388 |